This brand name is authorized in Canada, Israel, Japan
The drug ISTODAX contains one active pharmaceutical ingredient (API):
|
1
Romidepsin
UNII CX3T89XQBK - ROMIDEPSIN
|
|
Romidepsin is a histone deacetylase (HDAC) inhibitor. In vitro, romidepsin causes the accumulation of acetylated histones, and induces cell cycle arrest and apoptosis of some cancer cell lines with IC50 values in the nanomolar range. The mechanism of the antineoplastic effect of romidepsin observed in nonclinical and clinical studies has not been fully characterized. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01XH02 | Romidepsin | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XH Histone deacetylase (HDAC) inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: CA | Health Products and Food Branch | Identifier(s): 02414295 |
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 7089 |
| Country: JP | 医薬品医療機器総合機構 | Identifier(s): 4291440D1026 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
